Hsp90 chaperone facilitates E2F1/2-dependent gene transcription in human breast cancer cells

Attwooll, 2004, The E2F family: specific functions and overlapping interests, EMBO J., 23, 4709, 10.1038/sj.emboj.7600481 Bagatell, 2001, Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer, Clin. Cancer Res., 7, -2084 Bhaskara, 2008, Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control, Mol. Cell, 30, 61, 10.1016/j.molcel.2008.02.030 Calderwood, 2016, Hsp90 in Cancer: transcriptional roles in the nucleus, Adv. Cancer Res., 129, 89, 10.1016/bs.acr.2015.08.002 Choudhary, 2009, Lysine acetylation targets protein complexes and co-regulates major cellular functions, Science., 325, 834, 10.1126/science.1175371 Csermely, 1994, The 90 kDa heat shock protein (hsp90) induces the condensation of the chromatin structure, Biochem. Biophys. Res. Commun., 202, 1657, 10.1006/bbrc.1994.2124 Csermely, 1998, The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review, Pharmacol. Ther., 79, 129, 10.1016/S0163-7258(98)00013-8 Cuitiño, 2019, Two distinct E2F transcriptional modules drive cell cycles and differentiation, Cell Rep., 27, 10.1016/j.celrep.2019.05.004 da Silva, 2012, The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: A target for cancer therapeutics, J. Proteomics, 75, 2790, 10.1016/j.jprot.2011.12.028 Dimova, 2005, The E2F transcriptional network: old acquaintances with new faces, Oncogene, 24, 2810, 10.1038/sj.onc.1208612 Dyson, 1998, The regulation of E2F by pRB-family proteins, Genes Dev., 12, 2245, 10.1101/gad.12.15.2245 Fang, 2006, The transcription factor E2F: a crucial switch in the control of homeostasis and tumorigenesis, Histol. Histopathol., 21, 403 Goetz, 2003, The Hsp90 chaperone complex as a novel target for cancer therapy, Ann. Oncol., 14, 1169, 10.1093/annonc/mdg316 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell., 144, 646, 10.1016/j.cell.2011.02.013 Hiebert, 1989, E1A-dependent trans-activation of the human MYC promoter is mediated by the E2F factor, Proc. Natl. Acad. Sci. U.S.A., 86, 3594, 10.1073/pnas.86.10.3594 Ho, 2002, Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes, Curr. Opin. Genet. Dev., 12, 47, 10.1016/S0959-437X(01)00263-5 Isaacs, 2016, Hsp90 as a "Chaperone" of the Epigenome: Insights and Opportunities for Cancer Therapy, Adv. Cancer Res., 129, 107, 10.1016/bs.acr.2015.09.003 Javanmoghadam-Kamrani, 2008, Synchronization of the cell cycle using lovastatin, Cell Cycle, 7, 2434, 10.4161/cc.6364 Jin, 2020, Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression, Oncol. Lett., 19, 858 Johnson, 1994, Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression, Genes Dev., 8, 1514, 10.1101/gad.8.13.1514 Kamal, 2003, A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors, Nature, 425, 407, 10.1038/nature01913 Kent, 2019, The broken cycle: E2F dysfunction in cancer, Nat. Rev. Cancer, 19, 326, 10.1038/s41568-019-0143-7 Kotwal, 2020, Hsp90 regulates HDAC3-dependent gene transcription while HDAC3 regulates the functions of Hsp90, Cell. Signal., 76, 10.1016/j.cellsig.2020.109801 Kovacs, 2005, HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor, Mol. Cell, 18, 601, 10.1016/j.molcel.2005.04.021 Kumar, 2020, The matrix metalloproteinase 7 (MMP7) links Hsp90 chaperone with acquired drug resistance and tumor metastasis, Cancer Rep (Hoboken)., e1261 La Thangue, 1994, DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell-cycle control, Trends Biochem. Sci., 19, 108, 10.1016/0968-0004(94)90202-X Lammens, 2009, Atypical E2Fs: new players in the E2F transcription factor family, Trends Cell Biol., 19, 111, 10.1016/j.tcb.2009.01.002 Madoc-Jones, 1968, Interphase action of vinblastine and vincristine: differences in their lethal action through the mitotic cycle of cultured mammalian cells, J. Cell. Physiol., 72, 185, 10.1002/jcp.1040720306 Miyata, 2013, The therapeutic target Hsp90 and cancer hallmarks, Curr. Pharm. Des., 19, 347, 10.2174/138161213804143725 Ory, 2016, Blocking HSP90 addiction inhibits tumor cell proliferation, metastasis development, and synergistically acts with zoledronic acid to delay osteosarcoma progression, Clin. Cancer Res., 22, 2520, 10.1158/1078-0432.CCR-15-1925 Park, 2020, Unleashing the full potential of Hsp90 inhibitors as cancer therapeutics through simultaneous inactivation of Hsp90, Grp94, and TRAP1, Exp. Mol. Med., 52, 79, 10.1038/s12276-019-0360-x Pinzi, 2020, Design of dual inhibitors of histone deacetylase 6 and heat shock protein 90, ACS Omega, 5, 11473, 10.1021/acsomega.0c00559 Pratt, 1998, The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors, Proc. Soc. Exp. Biol. Med., 217, 420, 10.3181/00379727-217-44252 Pratt, 2004, Role of molecular chaperones in steroid receptor action, Essays Biochem., 40, 41, 10.1042/bse0400041 Queitsch, 2002, Hsp90 as a capacitor of phenotypic variation, Nature., 417, 618, 10.1038/nature749 Rutherford, 1998, Hsp90 as a capacitor for morphological evolution, Nature., 396, 336, 10.1038/24550 Sahasrabudhe, 2017, The plasticity of the Hsp90 Co-chaperone system, Mol. Cell, 67, 947, 10.1016/j.molcel.2017.08.004 Seto, 2014, Erasers of histone acetylation: the histone deacetylase enzymes, Cold Spring Harbor Perspect. Biology., 6, 10.1101/cshperspect.a018713 Sidera, 2014, HSP90 inhibitors: current development and potential in cancer therapy, Recent Pat. Anticancer Drug Discov., 9, 1, 10.2174/15748928113089990031 Singh, 2016, The cell killing mechanisms of hydroxyurea, Genes., 7, 99, 10.3390/genes7110099 Sreedhar, 2004, Inhibition of Hsp90: a new strategy for inhibiting protein kinases, Biochim. Biophys. Acta, 1697, 233, 10.1016/j.bbapap.2003.11.027 Telles, 2012, Modulation of cell cycle regulators by HDACs, Fron. Biosci. (Scholar edition), 4, 831 Vykuntham, 2020, Altered molecular pathways decides the treatment outcome of Hsp90 inhibitors against breast cancer cells, Toxicol. In Vitro, 65, 10.1016/j.tiv.2020.104828 Wang, 2020, Integrated analysis of the E2F transcription factors across cancer types, Oncol. Rep., 43, 1133 Weidenauer, 2017, Proteomic interrogation of HSP90 and insights for medical research, Expert Rev. Proteomics, 14, 1105, 10.1080/14789450.2017.1389649 Whitesell, 2005, HSP90 and the chaperoning of cancer, Nat. Rev. Cancer, 5, 761, 10.1038/nrc1716 Whitesell, 1998, The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent, Mol. Cell. Biol., 18, 1517, 10.1128/MCB.18.3.1517 Wu, 2017, Heat shock proteins and Cancer, Trends Pharmacol. Sci., 38, 226, 10.1016/j.tips.2016.11.009 Zhang, 2018, A critical role of E2F transcription factor 2 in proinflammatory cytokines-dependent proliferation and invasiveness of fibroblast-like synoviocytes in rheumatoid Arthritis, Sci. Rep., 8, 2623, 10.1038/s41598-018-20782-7 Zhu, 2004, E2Fs link the control of G1/S and G2/M transcription, EMBO J., 23, 4615, 10.1038/sj.emboj.7600459